Skip to main content
. Author manuscript; available in PMC: 2009 Mar 1.
Published in final edited form as: Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1037–1047. doi: 10.1167/iovs.07-1279

FIGURE 5.

FIGURE 5

Differential subcellular distribution of FKBP51 in normal NTM-5 and glaucomatous GTM-3 cells. Confluent NTM-5 and GTM-3 cells were treated with vehicle (control) or 100 nM DEX treatment for 30 minutes. The cytosol (100 µg) and nuclear (50 µg) fraction proteins were prepared and resolved on 4% to 15% gradient SDS-polyacrylamide gels. (A) Western immunoblot analysis with anti-FKBP52 antibody to detect the subcellular expression of FKBP52 under control or DEX treatment in GTM-3 and NTM-5 cells, as indicated. (B) Western immunoblot analysis with anti-FKBP51 antibody to detect the subcellular expression of FKBP51 under control or DEX treatment in GTM-3 and NTM-5 cells. The presented data are representative of three independent experiments.